ONO-4538 Phase I Study in Patients With Solid Tumor

• Status: Completed
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of the study is to investigate the pharmacokinetics of ONO-4538 administered to Korean patients with advanced or recurrent solid tumors who are refractory or intolerant to standard therapy or for whom no appropriate treatment is available.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ono Pharmaceutical Co. Ltd
• Treatments: Antibodies, Monoclonal; Nivolumab

Criteria

Inclusion Criteria:

• Male or female ≥ 20 years of age

• Histologically or cytologically confirmed solid tumor

• Patients with advanced or recurrent solid tumors who are refractory or intolerant to standard therapy or for whom no appropriate treatment is available

• ECOG Performance Status is 0 to 1

Exclusion Criteria:

• Current or prior severe hypersensitivity to another antibody product

• Multiple primary cancers